FIELD: pharmaceutics.
SUBSTANCE: invention refers to medicinal agents possessing cardioprotective action. Disclosed is use of lithium ascorbate as an agent possessing cardioprotective activity.
EFFECT: extended range of products possessing cardioprotective activity.
1 cl, 2 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
CARDIOPROTECTIVE AGENT | 2020 |
|
RU2743764C1 |
METHOD FOR SIMULATION OF INCREASED STABILITY OF RAT MYOCARDIUM TO ISCHEMIC-REPERFUSION DAMAGE | 2016 |
|
RU2623727C1 |
MEANS INCREASING HEART RESISTANCE TO REPERFUSION DAMAGE | 2016 |
|
RU2642826C1 |
AGENT IMPROVING CARDIAC RESISTANCE TO ISCHEMIC AND FOLLOWING REPERFUSION INJURIES | 2012 |
|
RU2488404C1 |
CARDIOPROTECTIVE AND ANTIARRHYTHMIC MEDICINE | 2022 |
|
RU2783444C1 |
AGENT WITH CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2791641C2 |
METHOD OF CARDIOPROTECTION OF ISCHEMIC AND REPERFUSION INJURIES IN ACUTE MYOCARDIAL INFARCTION | 2019 |
|
RU2712448C1 |
AGENT HAVING CARDIOPROTECTIVE ACTION AND 1,3-DISUBSTITUTED 2-AMINOBENZIMIDAZOLIUM HALIDES | 2013 |
|
RU2526902C1 |
AGENT SIMULATING CARDIAC POSTCONDITIONING PHENOMENON | 2012 |
|
RU2502508C1 |
IMPROVING THE RECOVERY FUNCTION OF THE CARDIOVASCULAR SYSTEM IN ISCHEMIA TETRADECAPEPTIDES | 2017 |
|
RU2648846C1 |
Authors
Dates
2019-09-03—Published
2019-03-25—Filed